Regency Capital Management Inc. DE lowered its position in Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) by 12.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 538,584 shares of the company’s stock after selling 74,105 shares during the period. Regency Capital Management Inc. DE owned 0.85% of Aura Biosciences worth $2,935,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after acquiring an additional 2,104 shares during the last quarter. Water Island Capital LLC bought a new position in shares of Aura Biosciences in the third quarter valued at approximately $64,000. 49 Wealth Management LLC bought a new position in shares of Aura Biosciences in the third quarter valued at approximately $66,000. ProShare Advisors LLC bought a new position in shares of Aura Biosciences in the fourth quarter valued at approximately $59,000. Finally, Invesco Ltd. bought a new position in shares of Aura Biosciences in the second quarter valued at approximately $76,000. Institutional investors own 96.75% of the company’s stock.
Aura Biosciences Price Performance
AURA stock opened at $6.80 on Friday. The company has a 50 day moving average price of $7.24 and a 200 day moving average price of $6.29. Aura Biosciences, Inc. has a fifty-two week low of $4.73 and a fifty-two week high of $9.53. The stock has a market capitalization of $703.05 million, a PE ratio of -3.91 and a beta of 0.39.
Insider Activity at Aura Biosciences
In other Aura Biosciences news, major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $5.64, for a total transaction of $39,044,986.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Conor Kilroy sold 11,738 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $7.02, for a total value of $82,400.76. Following the completion of the transaction, the insider owned 217,835 shares in the company, valued at $1,529,201.70. This represents a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.30% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on AURA shares. Weiss Ratings cut shares of Aura Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. HC Wainwright boosted their price objective on shares of Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Leerink Partners set a $17.00 price objective on shares of Aura Biosciences in a research report on Tuesday, May 12th. Finally, Wall Street Zen upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Aura Biosciences presently has a consensus rating of “Hold” and an average target price of $20.50.
Get Our Latest Stock Report on Aura Biosciences
Aura Biosciences Profile
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Featured Stories
- Five stocks we like better than Aura Biosciences
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Want to see what other hedge funds are holding AURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aura Biosciences, Inc. (NASDAQ:AURA – Free Report).
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
